Fed Governor Adriana Kugler to resign
LONDON - Advanced Medical (TASE:BLWV) Solutions Group plc ( AMS (VIE:AMS2)), a leading developer and manufacturer of innovative tissue-healing technology, acknowledged today that Montagu Private Equity LLP has made an announcement regarding a potential offer for the company. AMS confirmed that it has not yet received a formal proposal from Montagu.
According to the City Code on Takeovers and Mergers, Montagu must clarify its intentions by 5:00 p.m. (London time) on April 24, 2025. By this date, Montagu is required to either announce a definitive intention to make an offer in accordance with Rule 2.7 of the Code or declare that it will not make an offer, which would then be treated as a final statement under Rule 2.8 of the Code. The deadline may be extended with the Takeover Panel’s consent.
The announcement has triggered an "offer period" as defined in the Code. Consequently, AMS shareholders are advised to be aware of the dealing disclosure requirements set out in Rule 8 of the Code.
AMS’s product portfolio includes tissue adhesives, sutures, haemostats, internal fixation devices, and sealants, marketed under various brands such as LiquiBand®, RESORBA®, and ActivHeal®. The company has a global presence, with products manufactured across the UK, Germany, France, the Netherlands, Thailand, India, the Czech Republic, and Israel, and distributed via a network of partners and direct sales forces.
As of the date of this announcement, AMS has 217,988,053 ordinary shares in issue, admitted to trading on AIM of the London Stock Exchange (LON:LSEG), with the same number of voting rights. The International Securities Identification Number for AMS’s ordinary shares is GB0004536594.
AMS has engaged Evercore Partners (NYSE:EVR) International LLP and Investec (LON:INVP) Bank PLC as its financial advisers in relation to this matter.
This information is based on a press release statement and does not constitute an offer or an invitation to purchase shares in AMS. The company has not independently verified the information in the announcement and makes no representation regarding the accuracy or completeness of the information. Forward-looking statements contained herein are subject to risks and uncertainties, and actual events may differ materially from those projected.
Shareholders and potential investors are cautioned not to place undue reliance on these forward-looking statements, which reflect the company’s position only as of the date of this announcement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.